| Literature DB >> 31511620 |
Raquel Leao Orfali1, Fabio Seiti Yamada Yoshikawa2, Luanda Mara da Silva Oliveira2, Natalli Zanete Pereira2, Josenilson Feitosa de Lima2, Yasmim Álefe Leuzzi Ramos2, Alberto José da Silva Duarte2, Maria Notomi Sato2, Valeria Aoki2.
Abstract
Staphylococcus aureus colonizes the skin of atopic dermatitis (AD) individuals, but the impact of its enterotoxins on the chronic activation of CD4+ T cells demands further analysis. We aimed to analyze the CD4+ T cell anergy profile and their phenotypic and functional features through differential expression of cellular activation markers, cytokine production and response to staphylococcal enterotoxin A (SEA). A panel of 84 genes relevant to T cell anergy was assessed by PCR array in FACS-sorted CD4+ T cells, and the most prominent genes were validated by RT-qPCR. We evaluated frequencies of circulating CD4+ T cells secreting single or multiple (polyfunctional) cytokines (IL-17A, IL-22, TNF, IFN-γ, and MIP-1β) and expression of activation marker CD38 in response to SEA stimulation by flow cytometry. Our main findings indicated upregulation of anergy-related genes (EGR2 and IL13) promoted by SEA in AD patients, associated to a compromised polyfunctional response particularly in CD4+CD38+ T cells in response to antigen stimulation. The pathogenic role of staphylococcal enterotoxins in adult AD can be explained by their ability to downmodulate the activated effector T cell response, altering gene expression profile such as EGR2 induction, and may contribute to negative regulation of polyfunctional CD4+ T cells in these patients.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31511620 PMCID: PMC6739319 DOI: 10.1038/s41598-019-49421-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Staphylococcal enterotoxins drive CD4+ T cells to an anergic profile in AD. (a) Heatmap of the relative expression values of 84 key genes related to T-cell anergy in FACS-sorted CD4+ T cells analyzed by PCR array. The genes were classified according to functional criteria expressed on a thermal scale for HC (n = 3) and AD patients (n = 3) at baseline and after SEA stimulation. Expression of upregulated genes EGR2 (b) and IL13 (c) was confirmed by RT-qPCR (n = 8–9). Bars represent median with interquartile range. *p < 0.05.
Figure 2Impaired T cell cytokine secretion induced by SEA in AD. (a) Representative gating strategy for selection of CD3+CD4+ T cell population. Each subsequent panel shows only the population of interest producing each studied cytokine after SEA stimulation. (b) Frequencies of CD4+ T cells individually stained for IFN-γ, IL-17A, IL-22, MIP-1β or TNF after SEA stimulation from HC (n = 10) and AD patients (n = 15). Lines represent median with interquartile range. *p < 0.05, **p < 0.01, ***p < 0.001. (c) PCA of the CD4+ T cells polyfunctional profile. Boolean gating was used to calculate the proportions of polyfunctional T cells after SEA stimulation and frequency values were considered for analysis. Each dot represents one subject. PC, principal component.
Figure 3The high frequency of ex vivo CD4+CD38+ polyfunctional T cells is associated with a dysfunctional response to SEA in AD patients. (a) Representative gating strategy for analysis of cytokines and CD38 in CD4+ T cells. (b) Frequencies of CD4+CD38+/CD4+CD38− T cells in HC (n = 10) and AD patients (n = 15) in unstimulated condition. Bars represent median values. *p < 0.05. (c,d) PCA of the polyfunctional profile of CD4+CD38+ and CD4+CD38− T cells. Boolean gating was used to calculate the proportions of polyfunctional T cells after SEA stimulation and frequency values were considered for analysis. Each dot represents one subject. PC, principal component.
Demographic data of adults with AD.
| Identification | Gender | Age (years) | EASI | IgE (IU/mL) | Eosinophils % |
|---|---|---|---|---|---|
| AD1 | M | 30 | 48.4 | 18,300 | 6.6 |
| AD2 | M | 29 | 40.2 | 16,700 | 19.4 |
| AD3 | F | 39 | 31.6 | 6,120 | 5.2 |
| AD4 | M | 28 | 40.2 | 16,700 | 6.4 |
| AD5 | M | 24 | 48.9 | 3,120 | 10.1 |
| AD6 | F | 37 | 48.4 | 59,900 | 5.1 |
| AD7 | M | 43 | 18.4 | 28,300 | 12.7 |
| AD8 | F | 24 | 49 | 21,200 | 5.2 |
| AD9 | M | 24 | 50 | 46,300 | 22 |
| AD10 | M | 39 | 35.4 | 5,080 | 6.7 |
| AD11 | F | 20 | 34.8 | 119,000 | 5.5 |
| AD12 | M | 20 | 14.4 | 4,910 | 7.6 |
| AD13 | F | 21 | 48.2 | 54,200 | 9.9 |
| AD14 | F | 29 | 11.2 | 4,070 | 14.2 |
| AD15 | M | 21 | 38.5 | 2,870 | 6.8 |
| HC (n = 10) | 7 F/3 M | 29.7 (24–41) | NA | <100 | <5 |
AD = atopic dermatitis; HC = healthy controls; M = male; F = female; EASI = Eczema Area and Severity Index; NA = not applicable.